ARTICLE | Regulation
Roche building bispecific franchise outside oncology with Vabysmo approval
Ophthalmic bispecific Vabysmo reaches crowded AMD, DME market with blockbuster potential
February 1, 2022 2:10 AM UTC
Roche adds a second non-oncology bispecific with blockbuster potential to its product portfolio with the approval of Vabysmo, further proof that bispecific antibodies are set to make an impact on drug ...
BCIQ Company Profiles